China has established comprehensive national and industry standards for every major cardiovascular implant category. The Safety and Performance Basic Principles (EP Checklist) framework, adapted from IMDRF 2018, is the systematic foundation for all Class III technical review. Clinical evaluation pathways include direct clinical trials, equivalence-based evaluation, and use of overseas data — each with specific NMPA requirements. Biocompatibility and particle contamination are the most commonly cited deficiency areas in cardiovascular device submissions.
Achieving NMPA registration for a cardiovascular implantable device requires more than market access strategy — it demands a thorough, technically rigorous dossier that demonstrates safety and efficacy through a systematic evidence framework. China's regulatory system has matured significantly, and NMPA reviewers approach cardiovascular device submissions with deep technical expertise.
This article — based on guidance from former NMPA reviewers and the Centre for Medical Device Evaluation's (CMDE) published guidance documents — provides a detailed examination of the technical standards, clinical evaluation pathways, and common submission pitfalls for cardiovascular implantable devices.
1. The Safety and Performance Basic Principles Framework
The cornerstone of China's medical device technical review is the Safety and Performance Basic Principles (基本原则), which China adopted by equivalently converting the IMDRF 2018 document. This framework reflects the collective experience and consensus of global regulatory authorities — and is the foundational reference for every NMPA registration decision.
The Basic Principles serve three core functions:
- Define the safety and performance requirements a device must demonstrate throughout its entire lifecycle and under GMP-controlled manufacturing
- Identify the specific risk points and performance requirements that must be addressed for different device types — including special provisions for absorbable, radiation-emitting, implantable, and drug-containing devices
- Provide a conformity assessment framework through the EP Checklist (基本原则符合性清单)
The EP Checklist: The Systematic Evidence Structure
The EP Checklist is submitted as part of the registration dossier and serves as the integrating document for the entire technical submission. For each applicable requirement in the Basic Principles, the manufacturer must:
- State whether the requirement applies to the device (and if not, justify the exclusion)
- Identify the conformity method used (standard test, internal test, literature review, equivalence argument, etc.)
- Reference the objective evidence that demonstrates conformity
NMPA's technical review uses the EP Checklist as its primary index — systematically working through each applicable requirement to confirm that the evidence is complete, the methods are appropriate, and no significant risk has been overlooked. A complete, well-structured EP Checklist is one of the most effective tools for a smooth technical review.
2. National Standards by Product Category
China has developed a comprehensive standards architecture for cardiovascular implantable devices. Compliance with applicable mandatory standards is a legal requirement under Article 7 of the Medical Device Supervision and Administration Regulations. Non-mandatory standards provide important technical benchmarks and are frequently referenced in guidance documents.
Vascular Stents
China's vascular stent standards system covers two levels:
General performance standards address: device description and intended use terminology; radial support force; bending/kinking resistance; pushability and torqueability; simulated use testing. The general standard defines the framework; product-specific standards and guidance provide the detailed test protocols.
Specific performance characterisation standards cover detailed test methods for: dimensional characterisation; elastic recoil; finite element analysis (FEA); three-point bending; stent fixation performance; radial load testing; in vitro pulsatile fatigue; axial, bending, and torsional fatigue durability. For drug-eluting stents, additional standards address drug coating uniformity, elution kinetics, and biocompatibility of the polymer coating separately from the metal scaffold.
Heart Valves and Valve Repair Devices
Cardiac valve devices are categorised for standards purposes by implantation approach and material:
- Surgical valves: divided into biological (tissue) valves and mechanical valves — separate standards address hydrodynamic performance, fatigue life, and durability requirements for each
- Transcatheter valves (TAVR/TMVR): subject to additional requirements for delivery system performance, valve-in-valve deployment, and long-term structural valve deterioration assessment
- Valve repair devices: including annuloplasty rings, leaflet clip devices (e.g. transcatheter mitral valve repair), and artificial chordae tendineae — each category has specific structural and functional requirements
Key standard requirements across valve categories: hydrodynamic performance (forward pressure drop, effective orifice area, regurgitant fraction), fatigue life (minimum 400 million cycles, equivalent to 10 years), durability testing, and biological tissue-specific requirements for glutaraldehyde fixation and residue limits.
Vascular Grafts
Standards for vascular prostheses address: dimensional design (inner diameter, wall thickness, length); porosity and water permeability; mechanical strength (burst pressure, suture retention strength); kink diameter/radius; dynamic radial compliance; and biocompatibility. Specific requirements differ between woven/knitted textile grafts, expanded PTFE grafts, and composite constructs.
Cardiac Occluders
For atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), and patent foramen ovale (PFO) occluders, standards address: metallic frame material specifications; occlusive membrane materials; occlusion performance; durability testing; and — critically — particulate contamination limits. Nitinol frame biocompatibility and nickel ion release are specific areas of regulatory scrutiny.
3. Technical Guidance Principles: The Three-Level System
Beyond mandatory standards, NMPA has built a 600+ document technical guidance framework that directly shapes submission expectations for cardiovascular devices:
| Level | Document Type | Role |
|---|---|---|
| Level 1 | General guidance principles (通用指导原则) | Implantable device general requirements; clinical trial protocols; stability studies; animal testing |
| Level 2 | Product-specific guidance principles (产品指导原则) | Device-category-specific requirements — e.g. TAVR registration review guidance, coronary DES clinical trial guidance, bioresorbable coronary scaffold animal study guidance |
| Level 3 | Technical review focus points (审评要点) | For products not yet covered by formal guidance; captures the current shared understanding of CMDE reviewers; updated with agility as new products emerge |
Guidance documents are not mandatory — but they represent CMDE reviewers' current technical understanding. A submission that diverges from guidance without clear scientific justification will generate deficiency letters. Companies should review all applicable guidance documents before finalising their dossier strategy.
4. Clinical Evaluation Pathways
Clinical evaluation for cardiovascular devices can follow several paths. Selecting the right pathway — and structuring the evidence to match NMPA's expectations for that pathway — is one of the most consequential decisions in the registration strategy.
Clinical Trial (临床试验)
For devices on China's List of Class III Medical Devices Requiring Clinical Trial Approval, a separate NMPA clinical trial approval is required before the trial can begin. This is a distinct step from the product registration process. CMDE offers pre-review of clinical trial protocols — a mechanism that was significantly strengthened by Document No. 53 (2024) — allowing companies to submit clinical protocols for feedback before committing to the full trial design. This pre-review opinion is treated as a binding reference in subsequent technical review.
NMPA has published dedicated clinical trial design guidance for cardiovascular implants. For the 13-07 category, the 2024 Clinical Trial Design Type Recommendations provide specific guidance on: whether a randomised controlled trial (RCT), single-arm study, or registry-based design is appropriate for each subcategory; recommended control devices and non-inferiority margins; minimum follow-up duration; primary endpoint selection; and statistical analysis considerations.
Equivalence-Based Clinical Evaluation (同品种临床评价)
For devices with substantial equivalence to a legally marketed device, clinical evaluation can be based on literature review and equivalence argumentation rather than a dedicated trial. NMPA's equivalence guidance requires demonstration of equivalence across: intended use, technical characteristics, biological safety, and clinical performance. For cardiovascular implants, equivalence arguments face significant scrutiny — minor differences in material composition, surface treatment, or delivery system design may be considered clinically significant differences that invalidate an equivalence claim.
Acceptance of Overseas Clinical Trial Data
China's guidance on accepting overseas clinical trial data allows cardiovascular device registrations to rely on non-China clinical evidence, subject to specific conditions. The data must be generated at qualified institutions in the country of origin, comply with GCP, and be scientifically complete and internally consistent. NMPA requires a specific analysis of:
- Technical review requirement differences: any differences between the overseas regulatory requirements under which the trial was conducted and China's requirements must be identified and addressed
- Patient population differences: ethnicity, disease prevalence patterns, comorbidity profiles, and standard-of-care differences between the overseas and Chinese patient populations must be evaluated for their impact on clinical outcomes
- Clinical trial condition differences: differences in operator experience, procedural protocols, and institutional standards of care
A documented successful case: Trireme Medical LLC's paclitaxel drug-coated peripheral balloon catheter received NMPA approval based on a multicentre, prospective, randomised, parallel-group, non-inferiority overseas trial (n=333, 313 randomised) comparing it to an approved drug-coated PTA balloon — with no China-specific trial required.
5. Common Technical Submission Issues
Based on published CMDE guidance on frequently encountered questions, several technical areas generate disproportionate deficiency letters in cardiovascular device submissions:
Biocompatibility Evaluation
The most common area of deficiency. Key issues include:
- Processing aids (加工助剂) controls: If a processing aid used in manufacturing is not fully removed and has potential safety implications, or if it poses significant risk requiring strict control, residual limits must be included in the product technical requirements. Supporting data for all processing aid controls must be submitted.
- Comparator device differences: When using biocompatibility data from a marketed device to support a new submission, any differences in material chemical composition (including component ratios), physical structure, surface characteristics, manufacturing process, sterilisation method, raw material suppliers, or (for liquid/wet-stored products) primary packaging must be identified and justified. Where differences exist, supplementary biocompatibility data — including leachable analysis and toxicological risk assessment — may be required.
- Separate evaluation for implant and delivery system: For cardiovascular devices consisting of a permanently implanted component and a delivery system (e.g. stents pre-loaded on delivery catheters, occluders), NMPA requires separate biocompatibility evaluations for the long-term implanted component and the delivery system, given their substantially different contact nature and duration.
- Drug-eluting stent cytotoxicity: The stent scaffold and delivery system must be evaluated separately. If cytotoxicity of the drug-containing stent component is elevated, root cause analysis is required, followed by comprehensive risk evaluation.
Particulate Contamination (微粒污染)
For blood-contacting circulatory devices, particulate contamination assessment is mandatory. Acceptable methods include: YY/T 1556-2017 Particulate Contamination Index method, or the Chinese Pharmacopoeia's insoluble particulate test. When using the insoluble particulate test, NMPA requires an upper particle size limit requirement to be specified and justified. Particulate requirements must be included in the product technical requirements document.
Glutaraldehyde Residue (for Transcatheter Valve Devices)
For transcatheter tricuspid and other biological tissue valves fixed with glutaraldehyde, the residual glutaraldehyde limit must be established for the valve after cleaning per the Instructions for Use. Applicants may determine the limit based on known human tolerable limits and product quality control requirements, using GB/T 16886.17 for guidance on allowable leachable limits from medical devices.
Product Technical Requirements
A frequent source of back-and-forth: product technical requirements (产品技术要求) must include all performance characteristics relevant to safety and efficacy, with test methods that are reproducible and discriminating. For complex cardiovascular devices, incomplete performance specifications — particularly for fatigue durability, dimensional tolerances, and coating characteristics — are common triggers for supplementary data requests.
The technical complexity of cardiovascular device NMPA submissions is often underestimated. Companies that treat the EP Checklist as a formality, select the wrong clinical evaluation pathway for their device-comparator combination, or submit biocompatibility data without addressing the comparator differences NMPA specifically requires — routinely encounter deficiency letter cycles that add 1–3 years to their timelines. The former NMPA reviewers on our team have assessed these dossiers from the inside. The difference between a first-round complete submission and a multi-round process is almost always preparation quality, not product quality.